Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 1
2008 2
2009 1
2010 1
2012 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2020 6
2021 20
2022 12
2023 12
2024 22
2025 21
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for maolin yan
Search for Shaolin Yan instead (1 results)
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
Lei Z, Ma W, Si A, Zhang Y, Yang F, Yu Q, Tang H, Xiao Q, Zhou J, Wang K, Tang Y, Han T, Yin G, Chen J, Liu X, Zhao H, Yu D, Luo T, Wang Q, Yan M, Mao X, Li J, Wang K, Li J, Zeng Y, Ding D, Chen T, Wu X, Xia Y, Wang K, Guo W, Zhu G, Gao S, Hüser N, Lau WY, Song T, Cheng S, Shen F, Cheng Z. Lei Z, et al. Among authors: yan m. Aliment Pharmacol Ther. 2023 Sep;58(6):611-622. doi: 10.1111/apt.17623. Epub 2023 Jun 22. Aliment Pharmacol Ther. 2023. PMID: 37349908
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y, Sun J, Wu M, Lau WY, Zheng S, Wang XH, Chen X, Fan J, Dong J, Cai J, Chen M, Chen Y, Cheng Z, Dai C, Shan J, Du CY, Fang C, Hu H, Ji Z, Jia W, Li G, Li J, Li J, Liu C, Liu F, Ma Y, Mao Y, Niu Z, Shen J, Shi J, Shi X, Song W, Sun HC, Tan G, Tao R, Wang X, Wen T, Wu L, Xia J, Xiang BD, Yan M, Ying M, Zhang L, Zhang X, Zeng ZC, Zhang Y, Zhang Z, Zhou J, Zhou C, Zhou J, Zhou L, Zhou X, Zhu J, Zhu Z, Zhang Q, Li Q, Cheng S. Yang Y, et al. Among authors: yan m. Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec. Liver Cancer. 2022. PMID: 36589726 Free PMC article. Review.
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).
Yang Y, Sun J, Cai J, Chen M, Dai C, Wen T, Xia J, Ying M, Zhang Z, Zhang X, Fang C, Shen F, An P, Cai Q, Cao J, Zeng Z, Chen G, Chen J, Chen P, Chen Y, Shan Y, Dang S, Guo WX, He J, Hu H, Huang B, Jia W, Jiang K, Jin Y, Jin Y, Jin Y, Li G, Liang Y, Liu E, Liu H, Peng W, Peng Z, Peng Z, Qian Y, Ren W, Shi J, Song Y, Tao M, Tie J, Wan X, Wang B, Wang J, Wang K, Wang K, Wang X, Wei W, Wu FX, Xiang B, Xie L, Xu J, Yan ML, Ye Y, Yue J, Zhang X, Zhang Y, Zhang A, Zhao H, Zhao W, Zheng X, Zhou H, Zhou H, Zhou J, Zhou X, Cheng SQ, Li Q; Chinese Association of Liver Cancer and Chinese Medical Doctor Association. Yang Y, et al. Liver Cancer. 2024 Oct 22;14(3):311-333. doi: 10.1159/000541622. eCollection 2025 Jun. Liver Cancer. 2024. PMID: 40547957 Free PMC article. Review.
Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.
Wang K, Feng J, Yu H, Cheng Y, Xiang Y, Liu Z, Qin Y, Liu E, Shan Y, Fan C, Zhai J, He D, Zhou H, Tang Y, Shi J, Guo W, Yan M, Yu L, Kudo M, Cheng S. Wang K, et al. Among authors: yan m. Signal Transduct Target Ther. 2025 Oct 6;10(1):328. doi: 10.1038/s41392-025-02427-0. Signal Transduct Target Ther. 2025. PMID: 41047409 Free PMC article. Clinical Trial.
Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China.
Zhang XP, Zhang TC, Wu FF, Li ZQ, Xiao ZH, Yu ZT, Wang K, Xu S, Jiang T, Lin C, Chen X, Tan G, Xia NX, Zhao WC, Yan ML, Xu YF, Tan XD, Lin JH, Ma YT, Tang YF, Ni QQ, Hu YL, Hu YR, Wang K, Zhang F, Gao QL, Fan RF, Wang ZQ, Chen ZL, Lu YM, Jiang HX, Liu ZH, Cheng SQ, Hu MG, Liu R. Zhang XP, et al. Hepatol Int. 2025 Aug;19(4):903-914. doi: 10.1007/s12072-025-10802-w. Epub 2025 Mar 10. Hepatol Int. 2025. PMID: 40063322
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.
Zhang X, Cai H, Peng W, Wang H, Wu J, Zhu X, Guo W, Xie F, Zhang Y, Wang M, Yu Y, Zhou Y, Li C, Shen J, Liu C, Yang Y, Jiang X, Li Q, Chen W, Shi Y, Lu W, Sun X, Feng X, Yan M, Cheng S, Wen T. Zhang X, et al. Among authors: yan m. Signal Transduct Target Ther. 2026 Jan 22;11(1):37. doi: 10.1038/s41392-025-02498-z. Signal Transduct Target Ther. 2026. PMID: 41565617 Free PMC article. Clinical Trial.
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
Tang H, Zhang W, Cao J, Cao Y, Bi X, Zhao H, Zhang Z, Liu Z, Wan T, Lang R, Sun W, Du S, Yang Y, Lu Y, Zeng D, Wu J, Duan B, Lin D, Li F, Meng Q, Zhou J, Xing B, Tian X, Zhu J, Gao J, Hao C, Wang Z, Duan F, Wang Z, Wang M, Liang B, Chen Y, Xu Y, Li K, Li C, Hu M, Wang Z, Cai S, Ji W, Xia N, Zheng W, Wang H, Li G, Zhu Z, Huang Z, Zhang W, Tao K, Liang J, Zhang K, Dai C, Li J, Qiu Q, Guo Y, Wu L, Ding W, Zhu Z, Gu W, Cao J, Wang Z, Tian L, Ding H, Li G, Zeng Y, Wang K, Yang N, Jin H, Chen Y, Yang Y, Xiu D, Yan M, Wang X, Han Q, Jiao S, Tan G, Wang J, Liu L, Song J, Liao J, Zhao H, Li P, Song T, Wang Z, Yuan J, Hu B, Yuan Y, Zhang M, Sun S, Zhang J, Wang W, Wen T, Yang J, Du X, Peng T, Xia F, Liu Z, Niu W, Liang P, Xu J, Zhao X, Zhu M, Wang H, Kuang M, Shen S, Cui X, Zhou J, Liu R, Sun H, Fan J, Chen X, Zhou J, Cai J, Lu S; Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Chinese Society of Liver Cancer, Liver Study Group of Surgery Committee of Beijing Medical Association; Editorial Board of the Chinese Journal of Hepatobiliary Surgery. Tang H, et al. Among authors: yan m. Biosci Trends. 2025 Jan 14;18(6):505-524. doi: 10.5582/bst.2024.01394. Epub 2024 Dec 25. Biosci Trends. 2025. PMID: 39721704 Free article.
104 results